Samplimy Medical AB is currently supported by STING, KTH Innovation, Almi and Vinnova, and thus receiving extensive support from in-house Business Development Coaches as well as additional support such as legal and patent counseling, proof-of-concept funding schemes, access to industry, mentoring, and investor networks.

We are developing two microneedle-based products for collection of biofluid samples from the skin in a minimally invasive manner. Our technologies (two patents pending in EU and USA) enable self-sampling, using devices that extract, measure the volume, and store the sample in a stable form. The obtained samples can then be shipped to a laboratory for analysis without the need for refrigeration or be treated as biohazardous, substantially simplifying the logistics.

We have already successfully tested two product prototypes to obtain and analyze patient samples and we have published a study with the ISF sampling device (https://onlinelibrary.wiley.com/doi/10.1002/adhm.202202564) We are currently in the process of publishing the results in a scientific journal also for the blood-sampling device and we have several ongoing clinical validation projects in collaboration with a set of partners and early paying customers.

Samplimy is set to operate and expand within a large worldwide multi-billion-dollar market bridging blood sampling, PoC diagnostics, and homecare, with possibilities to diversify and extend its offer to various aspects of point-of-care sampling and testing.